XML 92 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - AstraZeneca Agreements [Member] - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jul. 30, 2013
Dec. 31, 2017
Sep. 30, 2016
Dec. 31, 2015
Jun. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
U.S./RoW [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Expected upfront, non-contingent and time-based payments $ 374,000              
Development and regulatory approval milestones 550,000              
Commercial sales milestone 325,000              
Shared development costs       $ 233,000        
Additional consideration based on net sales description           Low 20% range    
Contingent payment 62,000              
Milestone payment, revenue recognition           $ 15,000 $ 0 $ 15,000
U.S./RoW [Member] | FibroGen, Inc. [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Shared development costs       $ 116,500        
U.S./RoW [Member] | Development Milestones [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Receipt of development milestone payment         $ 15,000      
China [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Development and regulatory approval milestones 161,000              
Commercial sales milestone 167,500              
Proceeds from upfront payments 28,200              
Contingent payment $ 20,000              
Estimated joint development service period     2018          
Estimated joint development extended service period     2020          
Milestone payment, revenue recognition   $ 15,000